IOncology

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.

On June 9, 2026, the 16th Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) officially commenced. The conference runs from June 9 to June 13 and features a series of dedicated sessions highlighting the latest advances in gastrointestinal oncology.

On June 9, 2026, the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting officially opened. The first day featured three dedicated ASCO Highlights sessions showcasing the latest advances in gastrointestinal oncology.

On June 9, the 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting officially commenced. On the opening day, three dedicated ASCO Highlights sessions showcased the latest advances from the global oncology community. Among them, the ASCO Rare Tumors and Rare Mutations Updates Session attracted more than 19,000 online viewers.

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.

On June 11, the online program of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting continued with a dedicated session, “ASCO Highlights: Precision Oncology and Novel Therapeutics.” The session was livestreamed across multiple platforms and attracted more than 15,000 online viewers.

On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more than 25,000 online viewers.

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania "Luigi Vanvitelli" (Italy), shared his view that robotic surgery will transform colorectal operating rooms, much like laparoscopy did.

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Prof. Federico Maria Mongardini from PIO XI Hospital, Italy – attending the symposium for the third consecutive year – shared his insights on multimodal deep learning, obesity management, and Italy‑China collaboration.

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.